Rutgers Cancer Institute | Strategic Alliance Partners

August 25, 2024

Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy.

July 30, 2024

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

June 20, 2024

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

June 13, 2024

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

April 04, 2024

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

March 30, 2024

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

March 26, 2024

Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.

March 05, 2024

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

February 22, 2024

George Raptis, MD, MBA, begins role at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.

February 16, 2024

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health will offer hepatic artery infusion therapy for patients with liver tumors.

February 16, 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

February 16, 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

February 13, 2024

Rutgers Cancer Institute of New Jersey has elevated 2 associate director functions to deputy director positions.

February 09, 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

February 09, 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

February 02, 2024

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

February 02, 2024

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

January 26, 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

January 26, 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

January 19, 2024

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.